EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics

Taiwo Adesoye iD, Debasish Tripathy iD, Kelly K Hunt, Khandan Keyomarsi iD

Cancers · 24.01.2024 · 16 (3) · 492

DOI: 10.3390/cancers16030492 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.01.2024. Verfasst von Taiwo Adesoye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 229 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH/NCI, Cancer Prevention and Research Institute of Texas (CPRIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Signal Transducer and Activator of Transcription 3 (STAT3) plays a significant role in diverse physiologic processes, including cell proliferation, differentiation, angiogenesis, and survival. STAT3 activation via phosphorylation of tyrosine and serine residues is a complex and tightly regulated process initiated by upstream signaling pathways with ligand binding to receptor and non-receptor-linked kinases. Through downstream deregulation of target genes, aberrations in STAT3 activation are implicated in tumorigenesis, metastasis, and recurrence in multiple cancers. While there have been extensive efforts to develop direct and indirect STAT3 inhibitors using novel drugs as a therapeutic strategy, direct clinical application remains in evolution. In this review, we outline the mechanisms of STAT3 activation, the resulting downstream effects in physiologic and malignant settings, and therapeutic strategies for targeting STAT3. We also summarize the pre-clinical and clinical evidence of novel drug therapies targeting STAT3 and discuss the challenges of establishing their therapeutic efficacy in the current clinical landscape.

Schlagwörter

Stichwörter der Autor:innen

STAT3cancertherapeutics

Autor:innen und Institutionen

  • Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Taiwo Adesoye, Debasish Tripathy, Khandan Keyomarsi

Förderung

  • NCI NIH HHS
  • NIH/NCI
  • Cancer Prevention and Research Institute of Texas (CPRIT)
  • NCI Paul Calabresi K12 Scholar award

Zitieren

APA

Adesoye, T., Tripathy, D., Hunt, K. K., & Keyomarsi, K. (2024). Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics. Cancers, 16(3), 492. https://doi.org/10.3390/cancers16030492

Vancouver

Adesoye T, Tripathy D, Hunt KK, Keyomarsi K. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics. Cancers. 2024;16(3):492. doi:10.3390/cancers16030492

BibTeX
@article{Adesoye2024,
  author = {Adesoye, Taiwo and Tripathy, Debasish and Hunt, Kelly K and Keyomarsi, Khandan},
  title = {Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {3},
  pages = {492},
  doi = {10.3390/cancers16030492}
}
Kostenlos starten →